Выбор темы
Выбор стиля шрифта
GlaxoSmithKline новости
12/09
Отчет иностранного эмитента (6-K) - GSK PLC
11/09
Отчет иностранного эмитента (6-K) - GSK PLC
11/09
Отчет иностранного эмитента (6-K) - GSK PLC
09/09
Отчет иностранного эмитента (6-K) - GSK PLC
20/08
Отчет иностранного эмитента (6-K) - GSK PLC
18/03
Отчет иностранного эмитента (6-K) - GSK PLC
01/03
Отчет иностранного эмитента (6-K) - GSK PLC
01/02
Отчет иностранного эмитента (6-K) - GSK PLC
01/02
Отчет иностранного эмитента (6-K) - GSK PLC
17/01
Отчет иностранного эмитента (6-K) - GSK PLC
29/11
Отчет иностранного эмитента (6-K) - GSK PLC
15/11
Отчет иностранного эмитента (6-K) - GSK PLC
01/11
Отчет иностранного эмитента (6-K) - GSK PLC
20/10
Отчет иностранного эмитента (6-K) - GSK PLC
27/09
Отчет иностранного эмитента (6-K) - GSK PLC
25/09
Отчет иностранного эмитента (6-K) - GSK PLC
11/09
Отчет иностранного эмитента (6-K) - GSK PLC
22/08
Отчет иностранного эмитента (6-K) - GSK PLC
24/07
Отчет иностранного эмитента (6-K) - GSK PLC
03/07
Отчет иностранного эмитента (6-K) - GSK PLC
16/06
Отчет иностранного эмитента (6-K) - GSK PLC
01/06
Отчет иностранного эмитента (6-K) - GSK PLC
18/04
Отчет иностранного эмитента (6-K) - GSK PLC
12/01
Отчет иностранного эмитента (6-K) - GSK PLC
21/12
Отчет иностранного эмитента (6-K) - GSK PLC
02/12
Отчет иностранного эмитента (6-K) - GSK PLC
25/10
Отчет иностранного эмитента (6-K) - GSK PLC
02/02
🔗
Proactive Investors: GlaxoSmithKline JV to receive US$1.25bn after HIV case settlement
29/01
🔗
Zacks Investment Research: GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
27/01
🔗
Proactive Investors: Chill Brands appoints former Mars and GSK general counsel as independent NED
27/01
🔗
Proactive Investors: Chill Brands Group appoints former Mars and GSK general counsel as independent NED
26/01
🔗
Zacks Investment Research: Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
22/01
🔗
Zacks Investment Research: GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
20/01
🔗
GuruFocus: Unilever Stands Pat on GlaxoSmithKline Decision
20/01
🔗
Zacks Investment Research: Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer
20/01
🔗
Reuters: Shareholder Terry Smith labels Unilever's GSK bid "near death experience"
20/01
🔗
CNN Business: Unilever ends pursuit of GSK's consumer health business
20/01
🔗
Proactive Investors: Unilever drops bid for GSK Consumer Healthcare venture
20/01
🔗
Reuters: Unilever shares gain after opting not to lift bid for GSK assets
19/01
🔗
Seeking Alpha: GlaxoSmithKline Rejects Offer For Their Consumer Health Unit
19/01
🔗
Reuters: Unilever will not increase 50-billion-pound offer for GSK consumer arm
19/01
🔗
Proactive Investors: GlaxoSmithKline names Tony Wood chief scientific officer to succeed Hal Barron
18/01
🔗
Seeking Alpha: Unilever And Glaxo - A Classic Arbitrage Example
18/01
🔗
Seeking Alpha: Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
17/01
🔗
GuruFocus: GlaxoSmithKline Says 'No' 3 Times
17/01
🔗
GuruFocus: GlaxoSmithKline - Catalysts Ahead
17/01
🔗
Reuters: Unilever's offer for GSK's consumer health raises doubts, questions over strategy
17/01
🔗
Proactive Investors: Unilever yet to demonstrate it would be the right owner of GSK's Consumer Healthcare division
17/01
🔗
Proactive Investors: GlaxoSmithKline shares rise after it rejects Unilever bid for its consumer healthcare division
17/01
🔗
Proactive Investors: Unilever intent on making big acquisitions in health, beauty and hygiene sectors despite knock-back in approach for GSK Consumer Healthcare
17/01
🔗
PYMNTS: GlaxoSmithKline, Unilever Spar Over Future of GSK's Consumer Health Business
16/01
🔗
Reuters: Unilever to weigh raising offer for Glaxo Consumer unit - Bloomberg
15/01
🔗
Reuters: Factbox-GSK's consumer health business
15/01
🔗
Reuters: Unilever offers 50 billion pounds for GSK unit -report
14/01
🔗
Zacks Investment Research: Glaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US
13/01
🔗
Market Watch: Vir, GSK ask FDA to update EUA for their monoclonal antibody to include intramuscular administration
12/01
🔗
Zacks Investment Research: Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US
12/01
🔗
Seeking Alpha: GlaxoSmithKline plc's (GSK) CEO Emma Walmsley Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)
12/01
🔗
GuruFocus: Glaxo CEO: 2022 Will be 'Landmark' Year for Company
11/01
🔗
Market Watch: GlaxoSmithKline, Vir shares up as U.S. orders more doses of COVID treatment sotrovimab
06/01
🔗
Market Watch: GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses
22/12
🔗
Yahoo Finance: Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says
21/12
🔗
Zacks Investment Research: Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug
21/12
🔗
Benzinga: Long-Acting HIV Treatment Backed By GSK, Pfizer Scores FDA Approval As Preventative Option
20/12
🔗
Zacks Investment Research: GSK vs. NVO: Which Stock Is the Better Value Option?
20/12
🔗
Zacks Investment Research: Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
20/12
🔗
Zacks Investment Research: Omicron Variant Puts COVID-19 Antibody Treatments in Focus
20/12
🔗
Proactive Investors: GlaxoSmithKline names ex-Tesco chief Sir Dave Lewis to chair consumer healthcare spin-off
20/12
🔗
Reuters: Former Tesco boss Lewis to chair GSK health spin-off
19/12
🔗
Reuters: GSK picks ex-Tesco chief Lewis to head spun-off consumer healthcare arm - Sky News
16/12
🔗
Seeking Alpha: GlaxoSmithKline: Healthcare GARP Following Separation
15/12
🔗
Benzinga: Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
09/12
🔗
Zacks Investment Research: Best Income Stocks to Buy for December 9th
08/12
🔗
Pulse2: GlaxoSmithKline (GSK): Why The Price Increased Today
07/12
🔗
Yahoo Finance: Omicron: GSK-Vir drug effective against COVID-19 variant, U.S. changes international travel rules
07/12
🔗
Benzinga: Medicago, GSK's Plant-Based COVID-19 Vaccine Candidate Hits 75% Efficacy Against Delta Strain
07/12
🔗
Business Insider: GlaxoSmithKline says its antibody drug works against all Omicron mutations in lab studies
07/12
🔗
Benzinga: Preclinical Data Shows GSK-Vir COVID-19 Drug Works Against All Omicron Mutations
07/12
🔗
Barrons: Glaxo and Vir Antibody Drug Works on Omicron Mutations, New Data Show
07/12
🔗
Proactive Investors: Covid drug co-developed by GlaxoSmithKline effective against Omicron variant, second preclinical study shows
07/12
🔗
GuruFocus: GlaxoSmithKline Makes Another Big Bet on Brain Drugs
04/12
🔗
GuruFocus: Narrative Pharmaceuticals: Omicron vs. GlaxoSmithKline and Vir's Treatment
03/12
🔗
Stockmarketcom: Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know
03/12
🔗
Zacks Investment Research: Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron
02/12
🔗
Barrons: Glaxo Antibody Drug Works Against Omicron, Tests Show
02/12
🔗
Benzinga: Vir Biotech - GSK's COVID-19 Antibody Shows Preclinical Activity Against Omicron Variant
02/12
🔗
Proactive Investors: GlaxoSmithKline COVID-19 drug effective against Omicron variant, data shows
02/12
🔗
Proactive Investors: GlaxoSmithKline drug effective against Omicron variant
29/11
🔗
Zacks Investment Research: Glaxo (GSK) Upgraded to Strong Buy: Here's Why
28/11
🔗
The Motley Fool: 1 High-Yield Dividend Stock Worth Buying Right Now
Загрузить еще